≥6 months to <5 yrs≥5 yrs10 mg/kg/dose IV/PO q12h10 mg/kg/dose IV/PO q24hDose limit: 750 mg/dose
Outpatient beta lactam allergyLevofloxacin 500 mg PO daily x 14 days
Community-acquired pneumonia, or sepsis: In patients with allergies to 1st line drugs; or in patients where IV therapy for coverage for Mycoplasma is needed
Bacterial Meningitis:
Sickle cell disease: Significant Beta-lactam allergy: Levofloxacin
Sickle cell disease: Significant Beta-lactam allergy: Levofloxacin ± Vancomycin
Limited Use Product
337
CAP with co-morbidity: Community-acquired pneumonia with co-morbid illnesses or failure to first-line therapy
LU Authorization Period: 1 year
338
COPD with risk: Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) with risk factors*; bronchiectasis.
LU Authorization Period: 1 year
339
Step-Down: Step-down therapy after parenteral therapy or hospital / emergency department discharge
LU Authorization Period: 1 year
977
Exceptional cases of allergy or intolerance to all other appropriate therapies
LU Authorization Period: 1 year
QTc prolongation
Dysglycemia
CNS toxicity including confusion, psychosis
Tendinopathy and rupture
GI upset
Weakness exacerbation in myasthenia gravis
Rash
Evaluation of organ system functions (renal, hepatic, and hematopoietic) is recommended periodically during therapy
The possibility of crystalluria should be assessed, hydration status
WBC and signs of infection
Number and type of stools/day for diarrhea
Signs and symptoms of tendonitis
Administration with food prolonged time to peak by ~1 hour and decreased the peak concentration by ~14% and ~25% for the tablet and oral solution, respectively
Management: Tablet may be administered without regard to food; oral solution should be administered at least 1 hour before or 2 hours after food
Round levofloxacin doses to nearest tablet (250 mg, 500 mg) or half tablet
Tablets may be crushed but will have a bitter taste when crushed